Extended Data Table 1.
Convalescent patient characteristics
| Variable | Total N=73 N (%) |
|---|---|
| Age (median [range]) | 49 (21–69) |
| Sex | |
| Female | 35 (47.9) |
| Male | 38 (52.1) |
| Race | |
| White | 66 (90.4) |
| Black | 1 (1.4) |
| Asian | 4 (5.5) |
| Other | 2 (2.7) |
| Comorbidities | |
| Asthma | 12 (16.2) |
| Lung disease | 0 (0) |
| Heart disease | 3 (4.1) |
| Hypertension | 13 (17.6) |
| Diabetes mellitus | 3 (4.1) |
| Cancer | 10 (13.5) |
| Autoimmune disease | 4 (5.4) |
| Hyperlipidemia | 8 (10.8) |
| Hypothyroidism | 5 (6.8) |
| Gastroesophageal reflux disease | 5 (6.8) |
| Other | 26 (35.1) |
| Obesity | 1 (1.4) |
| Solid organ transplant | 1 (1.4) |
| First symptom | |
| Cough | 12 (16.4) |
| Diarrhea | 1 (1.4) |
| Dyspnea | 2 (2.7) |
| Fatigue | 6 (8.2) |
| Fever | 22 (30.1) |
| Headache | 8 (11) |
| Loss of taste | 3 (4.1) |
| Malaise | 3 (4.1) |
| Myalgias | 9 (12.3) |
| Nasal congestion | 2 (2.7) |
| Nausea | 1 (1.4) |
| Night sweats | 1 (1.4) |
| Sore throat | 3 (4.1) |
| Symptom present during disease | |
| Fever | 62 (84.9) |
| Cough | 51 (69.9) |
| Dyspnea | 28 (38.4) |
| Nausea | 19 (26) |
| Vomiting | 9 (12.3) |
| Diarrhea | 38 (52.1) |
| Headaches | 46 (63) |
| Loss of taste | 39 (53.4) |
| Loss of smell | 39 (53.4) |
| Fatigue | 35 (47.9) |
| Malaise | 5 (6.8) |
| Myalgias or body aches | 32 (43.8) |
| Sore throat | 10 (13.7) |
| Chills | 22 (30.1) |
| Nasal congestion | 6 (8.2) |
| Other | 31 (42.5) |
| Duration of symptoms in days (median [range]) | 14 (1–43) |
| Days from symptom onset to SARS-CoV-2 PCR sample collection (median [range]) | 6 (0–36) |
| Days from positive SARS-CoV-2 PCR to 1-month blood sample collection (median [range]) | 32 (14–76) |
| Days from symptom onset to 1-month blood sample collection (median [range]) | 41 (21–83) |
| Hospitalization | 6 (8.2) |
| COVID medications | |
| Hydroxychloroquine | 2 (2.7) |
| Chloroquine | 1 (1.4) |
| Azithromycin | 14 (18.9) |
| Lopinavir/ritonavir | 0 (0) |
| Remdesivir | 0 (0) |
| Convalescent plasma | 0 (0) |
| None | 58 (79.5) |
| Other | 2 (2.7) |
| Month 4 | |
| Days from positive SARS-CoV-2 PCR to 4-month blood sample collection (median [range]) | 122 (102–192) |
| Days from symptom onset to 4-month blood sample collection (median [range]) | 131 (106–193) |
| Any symptom present month 4 visit | 24 (32.9) |
| Fever | 0 (0) |
| Cough | 1 (1.4) |
| Dyspnea | 7 (9.6) |
| Nausea | 1 (1.4) |
| Vomiting | 1 (1.4) |
| Diarrhea | 2 (2.7) |
| Headaches | 1 (1.4) |
| Loss or altered taste | 7 (9.6) |
| Loss or altered smell | 12 (16.4) |
| Fatigue | 9 (12.3) |
| Forgetfulness/brain fog | 8 (11) |
| Hair loss | 5 (6.8) |
| Other | 7 (9.6) |
| Joint pain | 3 (4.1) |
| Month 7 | |
| Days from positive SARS-CoV-2 PCR to 7-month blood sample collection (median [range]) | 216 (191–259) |
| Days from symptom onset to 7-month blood sample collection (median [range]) | 225 (194–268) |
| Any symptom present month 6 visit | 30 (41.1) |
| Fever | 1 (1.4) |
| Cough | 0 (0) |
| Dyspnea | 6 (8.2) |
| Nausea | 1 (1.4) |
| Vomiting | 0 (0) |
| Diarrhea | 1 (1.4) |
| Headaches | 3 (4.1) |
| Loss or altered taste | 8 (11) |
| Loss or altered smell | 11 (15.1) |
| Fatigue | 13 (17.8) |
| Forgetfulness/brain fog | 12 (16.4) |
| Hair loss | 2 (2.7) |
| Other | 11 (15.1) |
| Joint pain | 7 (9.6) |